The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

Lingfang XIA; Jun ZHU; Xiaohua WU

doi:10.19401/j.cnki.1007-3639.2023.11.001

您当前的位置：

首页 >

文章列表页 >

The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

Specialist' Commentary | 更新时间：2025-12-31

- The latest progress and prospect of gynecological tumor treatment at 2023 ESMO
- China Oncology Vol. 33, Issue 11, Pages: 969-980(2023)
- 作者机构：
  
  复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.11.001
  CLC： R737.3
- Received：10 November 2023，
  
  Revised：2023-11-15，
  
  Published：30 November 2023
- 稿件说明：
移动端阅览
Lingfang XIA, Jun ZHU, Xiaohua WU. The latest progress and prospect of gynecological tumor treatment at 2023 ESMO[J]. China Oncology, 2023, 33(11): 969-980.
DOI：

Lingfang XIA, Jun ZHU, Xiaohua WU. The latest progress and prospect of gynecological tumor treatment at 2023 ESMO[J]. China Oncology, 2023, 33(11): 969-980. DOI： 10.19401/j.cnki.1007-3639.2023.11.001.

摘要

妇科肿瘤（宫颈癌、卵巢癌和子宫内膜癌）领域在过去1年取得了诸多重磅性研究成果，包括手术治疗方式、局部晚期治疗模式及复发转移的新治疗探索等，尤其是免疫治疗、靶向治疗和抗体药物偶联物（antibody-drug conjugate，ADC）治疗等新兴治疗方式相较于传统的治疗模式，其研究开创了治疗的新纪元，为患者带来更多的治疗希望。本文总结2023年欧洲肿瘤内科学会（European Society for Medical Oncology，ESMO）年会中妇科肿瘤在手术治疗、放疗、化疗及新型靶向免疫治疗等方面的重大进展，以期更好地指导临床个体化精准治疗。

Abstract

Many major research achievements have been made in the past year in the field of gynecologic oncology (cervical cancer

ovarian cancer and endometrial cancer)

including surgical treatment

local advanced treatment mode and exploration of new treatments for recurrence and metastasis. Especially the research of emerging treatment methods such as immunotherapy

targeted therapy and antibody-drug conjugate therapy has opened a new era of treatment and brought more hopes for treatment to patients. This paper summarizes the major advances in surgical treatment

radiotherapy

chemotherapy and novel targeted immunotherapy for gynecologic oncology at 2023 Annual Meeting of European Society for Medical Oncology (ESMO)

in order to better guide the individualized precision treatment.

关键词

Keywords

references

郑荣寿 , 张思维 , 孙可欣 , 等 . 2016年中国恶性肿瘤流行情况分析 [J ] . 中华肿瘤杂志 , 2023 , 45 ( 3 ): 212 - 220 .

ZHENG R S , ZHANG S W , SUN K X , et al . Cancer statistics in China, 2016 [J ] . Chin J Oncol , 2023 , 45 ( 3 ): 212 - 220 .

MCCORMACK M , GALLARDO RINCÓN D , EMINOWICZ G , et al . A randomised phase Ⅲ trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial [J ] . Ann Oncol , 2023 , 34 : S1276 .

MILESHKIN L R , MOORE K N , BARNES E H , et al . Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial [J ] . Lancet Oncol , 2023 , 24 ( 5 ): 468 - 482 . DOI: 10.1016/S1470-2045(23)00147-X http://doi.org/10.1016/S1470-2045(23)00147-X

LORUSSO D , XIANG Y , HASEGAWA K , et al . Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: a randomized, double-blind, phase Ⅲ ENGOT-cx11/GOG-3047/KEYNOTE-A18 study [J ] . Ann Oncol , 2023 , 34 : S1279 -S1280. DOI: 10.1016/j.annonc.2023.10.032 http://doi.org/10.1016/j.annonc.2023.10.032 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041765 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041765

MAYADEV J , NUNES A T , LI M , et al . CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase Ⅲ, randomized, double-blind, multicenter study [J ] . Int J Gynecol Cancer , 2020 , 30 ( 7 ): 1065 - 1070 . DOI: 10.1136/ijgc-2019-001135 http://doi.org/10.1136/ijgc-2019-001135 https://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2019-001135 https://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2019-001135

LEATH C A , DENG W , MELL L K , et al . Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: results from NRG-GY006, a phase Ⅲ randomized trial [J ] . J Clin Oncol , 2023 , 41 ( 16_suppl ): 5502 . DOI: 10.1200/JCO.2023.41.16_suppl.5502 http://doi.org/10.1200/JCO.2023.41.16_suppl.5502 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5502 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5502

COLOMBO N , DUBOT C , LORUSSO D , et al . Pembrolizumab for persistent, recurrent, or metastatic cervical cancer [J ] . N Engl J Med , 2021 , 385 ( 20 ): 1856 - 1867 . DOI: 10.1056/NEJMoa2112435 http://doi.org/10.1056/NEJMoa2112435 http://www.nejm.org/doi/10.1056/NEJMoa2112435 http://www.nejm.org/doi/10.1056/NEJMoa2112435

MONK B J , COLOMBO N , TEWARI K S , et al . First-line pembrolizumab+chemotherapy versus placebo+chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826 [J ] . J Clin Oncol , 2023 : JCO2 300914.

LIU N , YANG Z , TANG D , et al . Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase Ⅱ study [J ] . Ann Oncol , 2023 , 34 : S509 .

GAO X , XU N , LI Z , et al . Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial [J ] . Lancet Oncol , 2023 , 24 ( 10 ): 1134 - 1146 . DOI: 10.1016/S1470-2045(23)00411-4 http://doi.org/10.1016/S1470-2045(23)00411-4

WU X , XIA L , ZHANG K , et al . Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer [J ] . Ann Oncol , 2023 , 34 : S1284 -S1285.

LEE J Y , WU L , BOONYAPIPAT S , et al . AdvanTIG-202: phaseⅡ randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC) [J ] . Ann Oncol , 2023 , 34 : S509 -S510.

VERGOTE I B , GONZALEZ MARTIN A , FUJIWARA K , et al . InnovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase Ⅲ study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer [J ] . Ann Oncol , 2023 , 34 : S1276 -S1277.

XIA B , JIANG W , CHEN J , et al . Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase Ⅱ clinical study [J ] . Ann Oncol , 2023 , 34 : S520 .

National Comprehensive Cancer Network . NCCN Guidelines for treatment of ovarian cancer, 2023 V2 [EB/OL ] . [2023-11-15 ] . https://www.nccn.org. https://www.nccn.org https://www.nccn.org

中国抗癌协会妇科肿瘤专业委员会 , 中国抗癌协会肿瘤多学科诊疗(MDT)专业委员会 , 中国医师协会肿瘤多学科诊疗专业委员会 . 妇科恶性肿瘤多学科诊疗中国专家共识(2022年版) [J ] . 中国癌症杂志 , 2022 , 32 ( 8 ): 747 - 756 . DOI: 10.19401/j.cnki.1007-3639.2022.08.010 http://doi.org/10.19401/j.cnki.1007-3639.2022.08.010

The Society of Gynecological Cancer of China Anti-Cancer Association, Multidisciplinary Diagnosis and Treatment (MDT) Committee of China Anti-Cancer Association , Multidisciplinary Cancer Diagnosis and Treatment Committee of Chinese Medical Doctor Association . Consensus of Chinese experts on multidisciplinary team of gynecological malignant tumors (2022 edition) [J ] . Chin Oncol , 2022 , 32 ( 8 ): 747 - 756 . DOI: 10.19401/j.cnki.1007-3639.2022.08.010 http://doi.org/10.19401/j.cnki.1007-3639.2022.08.010

WU X H , LIU J H , WANG X B , et al . Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): a randomized, double-blind, placebo-controlled, phase 3 trial [C ] . Late Breaking Abstracts. BMJ Publishing Group Ltd , 2023 .

FLOOR B , TIRZA A C B , JESSICA P , et al . Real-world time to treatment discontinuation of first-line maintenance niraparib monotherapy in epithelial ovarian cancer: CHAR1ZMA study [C ] . 2023 ESMO, Abs 789P .

KURTZ J E , PUJADE-LAURAINE E , OAKNIN A , et al . Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase Ⅲ ATALANTE/ENGOT-ov29 trial [J ] . J Clin Oncol , 2023 , 41 ( 30 ): 4768 - 4778 . DOI: 10.1200/JCO.23.00529 http://doi.org/10.1200/JCO.23.00529 https://ascopubs.org/doi/10.1200/JCO.23.00529 https://ascopubs.org/doi/10.1200/JCO.23.00529

PUJADE-LAURAINE E , FUJIWARA K , LEDERMANN J A , et al . Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study [J ] . Lancet Oncol , 2021 , 22 ( 7 ): 1034 - 1046 . DOI: 10.1016/S1470-2045(21)00216-3 http://doi.org/10.1016/S1470-2045(21)00216-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002163 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002163

HARTER P , TRILLSCH F , OKAMOTO A , et al . Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed adva nced ovarian cancer (AOC) without a tumor BRCA 1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase Ⅲ DUO-O trial [J ] . J Clin Oncol , 2023 , 41 ( 17_suppl ): LBA5506 . DOI: 10.1200/JCO.2023.41.17_suppl.LBA5506 http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA5506 https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA5506 https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA5506

GONZALEZ MARTIN A , RUBIO PEREZ M J , HEITZ F , et al . Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase Ⅲ trial [J ] . Ann Oncol , 2023 , 34 : S1278 -S1279. DOI: 10.1016/j.annonc.2023.10.031 http://doi.org/10.1016/j.annonc.2023.10.031 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041753 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041753

LIU J F , BRADY M , MATULONIS U A , et al . Overall survival (OS) outcomes from NRG-GY004, a phase Ⅲ study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) [J ] . Ann Oncol , 2023 , 34 : S1285 . DOI: 10.1016/j.annonc.2023.10.039 http://doi.org/10.1016/j.annonc.2023.10.039 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041832 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041832

LIU J F , BARRY W T , BIRRER M , et al . Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study [J ] . Lancet Oncol , 2014 , 15 ( 11 ): 1207 - 1214 . DOI: 10.1016/S1470-2045(14)70391-2 http://doi.org/10.1016/S1470-2045(14)70391-2

WU X , LIU J , WANG L , et al . SABRINA study: a phase Ⅱ study of senaparib monotherapy for patients (pts) with BRCA 1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC) [J ] . Ann Oncol , 2023 , 34 : S521 .

LEE J M . Randomized phase Ⅱ trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023) [J ] . Ann Oncol , 2023 , 34 : S511 .

MOORE K N , PHILIPOVSKIY A , HARANO K , et al . Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase Ⅰ study [J ] . Ann Oncol , 2023 , 34 : S510 . DOI: 10.1016/j.annonc.2023.09.1924 http://doi.org/10.1016/j.annonc.2023.09.1924 https://linkinghub.elsevier.com/retrieve/pii/S0923753423027618 https://linkinghub.elsevier.com/retrieve/pii/S0923753423027618

HOWLETT S , BERNER A M , CONNOLLY K , et al . Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients [J ] . Ann Oncol , 2023 , 34 : S535 .

DE BRUYN M , EERKENS A L , BRUMMEL K , et al . Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer [J ] . Ann Oncol , 2023 , 34 : S508 -S509.

MIRZA M R , SHARMA S , HERRSTEDT J , et al . Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial [J ] . Ann Oncol , 2023 , 34 : S507 . DOI: 10.1016/j.annonc.2023.09.1919 http://doi.org/10.1016/j.annonc.2023.09.1919 https://linkinghub.elsevier.com/retrieve/pii/S0923753423027564 https://linkinghub.elsevier.com/retrieve/pii/S0923753423027564

ESKANDER R N , SILL M , MILLER A , et al . Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial [J ] . Ann Oncol , 2023 , 34 : S1284 .

NICOLETTA C . Phase Ⅲ double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: ENGOT-en7/MaNGO/AtTEnd study [C ] . 2023 ESMO, Abs LBA40.

WESTIN S N , MOORE K N , CHON H S , et al . Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva±olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the phase Ⅲ DUO-E/GOG-3041/ENGOT-EN10 trial [J ] . Ann Oncol , 2023 , 34 : S1282 -S1283. DOI: 10.1016/j.annonc.2023.10.035 http://doi.org/10.1016/j.annonc.2023.10.035 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041790 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041790

JOLY LOBBEDEZ F , LEARY A , RAY-COQUARD I L , et al . Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: the GINECO randomized phase Ⅱb UTOLA trial [J ] . Ann Oncol , 2023 , 34 : S1283 -S1284. DOI: 10.1016/j.annonc.2023.10.036 http://doi.org/10.1016/j.annonc.2023.10.036 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041807 https://linkinghub.elsevier.com/retrieve/pii/S0923753423041807

POTHURI B , NAUMANN R W , MARTIN L P , et al . Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase Ⅰ dose expansion [J ] . Ann Oncol , 2023 , 34 : S508 .

Views

5696

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Progress in treatment of gynecological cancer in 2023

Progress in diagnosis and treatment of gynecological tumors in 2022

Leading research progress and prospect of gynecological oncology in 2020

Annual Progress Review of Gynecologic Malignancies in 2025

Related Author

Sumei FAN

Congling XIN

Laifang ZHU

Chang LIU

Rui XU

Zhengrong ZHOU

Xi CHENG

Zheng FENG

Related Institution

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Diagnostic Radiology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰